Schizophrenia News and Research

Latest Schizophrenia News and Research

Brain structure linked to psychosis symptoms

A study of patients across the psychosis spectrum supports an association between brain structure and psychosis symptoms.

11 Jun 2014

Study presents oxytocin as latest treatment target for age-related muscle wasting

Researchers at the University of California, Berkeley, have discovered that oxytocin -- a hormone associated with maternal nurturing, social attachments, childbirth and sex -- is indispensable for healthy muscle maintenance and repair, and that in mice, it declines with age.

11 Jun 2014

Alkermes initiates FORWARD-3 and FORWARD-4 efficacy studies in pivotal clinical program for ALKS 5461

Alkermes plc today announced the initiation of FORWARD-3 and FORWARD-4, two of the three planned phase 3 core efficacy studies in the pivotal clinical program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD).

10 Jun 2014

Kids at risk for mental disorders experience communication breakdown in brain networks

Attention deficits are central to psychiatric disorders such as schizophrenia or bipolar disorder, and are thought to precede the presentation of the illnesses.

9 Jun 2014

Researchers uncover several gene networks with potentially important roles in autism

A large new analysis of DNA from thousands of patients has uncovered several underlying gene networks with potentially important roles in autism.

9 Jun 2014

Gene networks may offer attractive targets for developing new autism drugs

A large new analysis of DNA from thousands of patients has uncovered several underlying gene networks with potentially important roles in autism.

6 Jun 2014

Brain networks supporting attention do not communicate correctly in children at risk for bipolar disorder

Attention deficits are central to psychiatric disorders such as schizophrenia or bipolar disorder, and are thought to precede the presentation of the illnesses.

6 Jun 2014

Brain circuit problem may contribute to auditory hallucinations of schizophrenia

St. Jude Children's Research Hospital scientists have identified problems in a connection between brain structures that may predispose individuals to hearing the "voices" that are a common symptom of schizophrenia. The work appears in the June 6 issue of the journal Science.

6 Jun 2014

Discovery may lead to relief for victims of range of neurological disorders

University of Toronto biologists leading an investigation into the cells that regulate proper brain function, have identified and located the key players whose actions contribute to afflictions such as epilepsy and schizophrenia.

6 Jun 2014

Study offers clues to best long-acting injectable antipsychotic use

Findings from the PROACTIVE study suggest why the benefits of long-acting injectable second-generation antipsychotics may be difficult to detect in a clinical trial.

5 Jun 2014

Risk factors for violence and death are not restricted to schizophrenia

Drug-use disorders, criminality and self-harm increase the risk for violent crime and premature death not only in patients with schizophrenia, but also in their unaffected siblings, researchers report.

5 Jun 2014

EC approves extension of INVEGA antipsychotic drug to include adolescents aged 15 years and older

Janssen-Cilag International NV announced today that the European Commission has approved an extension of the oral atypical antipsychotic INVEGA® (paliperidone ER) schizophrenia indication, to include adolescents aged 15 years and older.

4 Jun 2014

Autifony Therapeutics awarded £2.2 million to progress first-in-class drug for tinnitus into Phase IIa study

Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced that it has been awarded funding of £2.2 million towards a Phase IIa clinical trial in tinnitus patients with its lead compound AUT00063, by the UK’s innovation agency, the Technology Strategy Board.

4 Jun 2014

Study: Use of antipsychotic medication during pregnancy can affect babies

A seven-year study of women who take antipsychotic medication while pregnant, proves it can affect babies.

3 Jun 2014

Alkermes initiates second ALKS 3831 Phase 2 clinical study for treatment of schizophrenia

Alkermes plc today announced the initiation of the second phase 2 study of ALKS 3831, a novel, oral, broad-spectrum antipsychotic medicine in development for schizophrenia.

2 Jun 2014

Newron Pharmaceuticals submits safinamide NDA to FDA

Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area with a long experience in respiratory disease therapies, woman care and primary care, announce that the New Drug Application (NDA) for safinamide was submitted today to the US Food and Drug Administration (FDA).

30 May 2014

Researchers use patterned visual stimulation to control rapid re-wiring of nerve circuits

In a new study, published in this week's issue of the journal Science, researchers show for the first time how the brain re-wires and fine-tunes its connections differently depending on the relative timing of sensory stimuli.

29 May 2014

Study defines specific genetic mechanism that explains some of schizophrenia's heritability

The overall number and nature of mutations—rather than the presence of any single mutation—influences an individual's risk of developing schizophrenia, as well as its severity, according to a discovery by Columbia University Medical Center researchers published in the latest issue of Neuron.

29 May 2014

Drug use linked to persistent violence in psychosis patients

Patients with first-episode psychosis are more likely to report being involved in violence over subsequent years if they persist with illicit drug use, a 10-year study shows.

28 May 2014

Study gives hints about male versus female risk for certain psychiatric disorders

Puberty is the defining process of adolescent development, beginning a cascade of changes throughout the body, including the brain.

27 May 2014

Schizophrenia News and Research

Latest Schizophrenia News and Research

Brain structure linked to psychosis symptoms

Study presents oxytocin as latest treatment target for age-related muscle wasting

Alkermes initiates FORWARD-3 and FORWARD-4 efficacy studies in pivotal clinical program for ALKS 5461

Kids at risk for mental disorders experience communication breakdown in brain networks

Researchers uncover several gene networks with potentially important roles in autism

Gene networks may offer attractive targets for developing new autism drugs

Brain networks supporting attention do not communicate correctly in children at risk for bipolar disorder

Brain circuit problem may contribute to auditory hallucinations of schizophrenia

Discovery may lead to relief for victims of range of neurological disorders

Study offers clues to best long-acting injectable antipsychotic use

Risk factors for violence and death are not restricted to schizophrenia

EC approves extension of INVEGA antipsychotic drug to include adolescents aged 15 years and older

Autifony Therapeutics awarded £2.2 million to progress first-in-class drug for tinnitus into Phase IIa study

Study: Use of antipsychotic medication during pregnancy can affect babies

Alkermes initiates second ALKS 3831 Phase 2 clinical study for treatment of schizophrenia

Newron Pharmaceuticals submits safinamide NDA to FDA

Researchers use patterned visual stimulation to control rapid re-wiring of nerve circuits

Study defines specific genetic mechanism that explains some of schizophrenia's heritability

Drug use linked to persistent violence in psychosis patients

Study gives hints about male versus female risk for certain psychiatric disorders

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

Schizophrenia News and Research

Latest Schizophrenia News and Research

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

Newsletters you may be interested in